In the discussion of our report on the beneficial effects of sodium para-aminobenzoate (NaPAB) in certain forms of lupus erythematosus (1), Rein stated that he had treated 13 cases of chronic discoid lupus erythematosus with 22.5 grams of NaPAB1 daily and the results were poor in all cases. In addition he observed marked toxic reactions consisting of Ieukopeiiia, dissemination of lesions, generalized pruritus, and weakness. Furthermore, 
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he failed to demonstrate a reducing substance in the urine of patients taking NaPAB. Since this was an almost constant finding in our cases, it was believed possible that the product used by Dr. Rein might differ in some way from that which we had employed.2 For this reason, Dr. Rein kindly supplied us with about 100 grams of the compound which had been administered to his subjects. The quantity was insufficient for a clinical trial in lupus erythematosus. It was therefore decided to give it to two relatively normal patients and to determine whether a reducing substance appeared in the urine. The corn- pound was administered in doses of 3 grams every three hours. One patient, however, refused many of the doses. In table I are given the total daily dosages, the reaction of the urine with Benedict's solution, the white blood cell counts, and the PABA blood levels, taken 2 hours after each dose.
It should be noted that both of these patients had a reducing substance in the urine. This appeared within 24 hours after medication was begun, and cleared within 24 hours after its administration was stopped. In view of the finding of this reaction in the urine of both patients, it is difficult to explain the negative finding by Rein in 13 consecutive cases. It would seem that at least some of his patients would have shown a reducing substance had they taken the full amount of NaPAB prescribed.
The nature of the reducing substance was stated by us to be glucose, as a result of our findings with osazone and other tests. Fermentation reactions are not satisfactory because the concentration of NaPAB in the urine of patients under therapy generally inhibits yeast activity. Additional studies have given evidence that this substance may not be glucose. The results of that investigation will soon be reported (2) . The points which we wish to emphasize here are (1) that a reducing substance is usually present in the urine of patients receiving large doses of NaPAB, and (2) that we also obtained this finding with the NaPAB preparation used by Dr. Rein.
Our experience with NaPAB therapy in lupus erythematosus has now been extended to 30 patients, and the results remain generally in accord with those previously published (1).
